Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

ASCEND investigators

Research output: Contribution to journalArticle

62 Scopus citations

Fingerprint Dive into the research topics of 'Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension'. Together they form a unique fingerprint.

Medicine & Life Sciences